Andrea Sartore-Bianchi is medical oncologist at Grande Ospedale Metropolitano Niguarda in Milano, Italy, where he is director of the Division of Clinical Research and Innovation. He is associate professor of oncology at the University of Milano (La Statale).

He received his MD and postgraduate degree in oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics at Brown University, Providence, RI, USA.

Prof. Sartore-Bianchi’s main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, focusing on biomarkers of sensitivity/resistance to molecular targeted therapies and immunotherapy. He carried out seminal studies regarding RAS and Her2 as tumour tissue and ctDNA biomarkers for guiding treatment in colorectal cancer and he is principal and co-investigator in phase I-III clinical trials for solid tumours. He is involved in academic international collaborative projects focused on translational research in colorectal cancer.

He has published 200 peer-reviewed articles in various medical journals including Nature Medicine, Lancet Oncology and Annals of Oncology, with a H-index of 64 (Scopus).